Skip to main content
PMC home page
Health Services Research logoLink to Health Services Research
. 2001 Jun;36(2):357–371.

Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population.

L T Piecoro 1, M Potoski 1, J C Talbert 1, D E Doherty 1
PMCID: PMC1089228  PMID: 11409817

Abstract

OBJECTIVE: To provide a descriptive analysis of asthma prevalence and costs in a Medicaid population and gauge the degree of adherence with expert guidelines for asthma medication management from the National Asthma Education and Prevention Program. DATA SOURCES: Kentucky Medicaid administrative data for 1996. STUDY DESIGN: A cross-sectional retrospective analysis was used to determine adherence with asthma medication guidelines and utilization of asthma-related health care services and costs. Multivariate logistic regression was used to determine the relationship between nonadherence with the guidelines and utilization of health care services. PRINCIPAL FINDINGS: Of the 530,000 Medicaid recipients, 24,365 (4.6 percent) were identified as having asthma. Average annual asthma-related costs ($616) accounted for less than 20 percent of total health care costs ($3,645). Nonadherence to the guidelines was prevalent. Less than 40 percent of the patients received a prescription for a rescue medication, and fewer than 10 percent of the patients who received daily inhaled short-acting beta-2 agonists were regular users of inhaled steroids. Nonadherence to the guidelines was associated with an increased risk of an asthma-related hospitalization (odds ratio = 1.5, p < .05). CONCLUSIONS: Guideline nonadherence was widespread and associated with an increase in exacerbations of asthma that resulted in hospitalizations. Asthma prevalence and utilization of health care services in a Medicaid population were similar to previous estimates reported nationally and in health maintenance organizations.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong E. P., Manuchehri F. Ambulatory care databases for managed care organizations. Am J Health Syst Pharm. 1997 Sep 1;54(17):1973–2005. doi: 10.1093/ajhp/54.17.1973. [DOI] [PubMed] [Google Scholar]
  2. Balkrishnan R., Norwood G. J., Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin Ther. 1998 May-Jun;20(3):567–580. doi: 10.1016/s0149-2918(98)80066-0. [DOI] [PubMed] [Google Scholar]
  3. Blumenschein K., Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol. 1998 Feb;80(2):189–194. doi: 10.1016/S1081-1206(10)62954-7. [DOI] [PubMed] [Google Scholar]
  4. Bosco L. A., Gerstman B. B., Tomita D. K. Variations in the use of medication for the treatment of childhood asthma in the Michigan Medicaid population, 1980 to 1986. Chest. 1993 Dec;104(6):1727–1732. doi: 10.1378/chest.104.6.1727. [DOI] [PubMed] [Google Scholar]
  5. Donahue J. G., Weiss S. T., Livingston J. M., Goetsch M. A., Greineder D. K., Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997 Mar 19;277(11):887–891. [PubMed] [Google Scholar]
  6. Gerstman B. B., Bosco L. A., Tomita D. K. Trends in the prevalence of asthma hospitalization in the 5- to 14-year-old Michigan Medicaid population, 1980 to 1986. J Allergy Clin Immunol. 1993 Apr;91(4):838–843. doi: 10.1016/0091-6749(93)90340-l. [DOI] [PubMed] [Google Scholar]
  7. Gottlieb D. J., Beiser A. S., O'Connor G. T. Poverty, race, and medication use are correlates of asthma hospitalization rates. A small area analysis in Boston. Chest. 1995 Jul;108(1):28–35. doi: 10.1378/chest.108.1.28. [DOI] [PubMed] [Google Scholar]
  8. Joseph C. L., Havstad S. L., Ownby D. R., Johnson C. C., Tilley B. C. Racial differences in emergency department use persist despite allergist visits and prescriptions filled for antiinflammatory medications. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):484–490. doi: 10.1016/S0091-6749(98)70355-0. [DOI] [PubMed] [Google Scholar]
  9. Laumann J. M., Bjornson D. C. Treatment of Medicaid patients with asthma: comparison with treatment guidelines using disease-based drug utilization review methodology. Ann Pharmacother. 1998 Dec;32(12):1290–1294. doi: 10.1345/aph.18147. [DOI] [PubMed] [Google Scholar]
  10. Lewis N. J., Patwell J. T., Briesacher B. A. The role of insurance claims databases in drug therapy outcomes research. Pharmacoeconomics. 1993 Nov;4(5):323–330. doi: 10.2165/00019053-199304050-00003. [DOI] [PubMed] [Google Scholar]
  11. Motheral B. R., Fairman K. A. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther. 1997 Mar-Apr;19(2):346–366. doi: 10.1016/s0149-2918(97)80122-1. [DOI] [PubMed] [Google Scholar]
  12. Nestor A., Calhoun A. C., Dickson M., Kalik C. A. Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population. Ann Allergy Asthma Immunol. 1998 Oct;81(4):327–330. doi: 10.1016/S1081-1206(10)63124-9. [DOI] [PubMed] [Google Scholar]
  13. Ray W. A., Griffin M. R. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989 Apr;129(4):837–849. doi: 10.1093/oxfordjournals.aje.a115198. [DOI] [PubMed] [Google Scholar]
  14. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  15. Smith D. H., Malone D. C., Lawson K. A., Okamoto L. J., Battista C., Saunders W. B. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):787–793. doi: 10.1164/ajrccm.156.3.9611072. [DOI] [PubMed] [Google Scholar]
  16. Stempel D. A., Durcannin-Robbins J. F., Hedblom E. C., Woolf R., Sturm L. L., Stempl A. B. Drug utilization evaluation identifies costs associated with high use of beta-adrenergic agonists. Ann Allergy Asthma Immunol. 1996 Feb;76(2):153–158. doi: 10.1016/s1081-1206(10)63415-1. [DOI] [PubMed] [Google Scholar]
  17. Stempel D. A., Hedblom E. C., Durcanin-Robbins J. F., Sturm L. L. Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures. Arch Fam Med. 1996 Jan;5(1):36–40. doi: 10.1001/archfami.5.1.36. [DOI] [PubMed] [Google Scholar]
  18. Weiss K. B., Gergen P. J., Hodgson T. A. An economic evaluation of asthma in the United States. N Engl J Med. 1992 Mar 26;326(13):862–866. doi: 10.1056/NEJM199203263261304. [DOI] [PubMed] [Google Scholar]
  19. Wingert T. D., Kralewski J. E., Lindquist T. J., Knutson D. J. Constructing episodes of care from encounter and claims data: some methodological issues. Inquiry. 1995;32(4):430–443. [PubMed] [Google Scholar]
  20. Wissow L. S., Gittelsohn A. M., Szklo M., Starfield B., Mussman M. Poverty, race, and hospitalization for childhood asthma. Am J Public Health. 1988 Jul;78(7):777–782. doi: 10.2105/ajph.78.7.777. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Health Services Research are provided here courtesy of Health Research & Educational Trust

RESOURCES